Day: July 19, 2021

Figure 1Regional gravity image with gravity highs associated with the Blackwood Prospect and Greenbushes Giant LCT Pegmatite. WA 400m Gravity Merge.Figure 2A Distal pegmatite phase in the Blackwood Prospect, which contains elevated Lithium, Beryllium, Caesium, Rubidium, Tin and Tantalum.Figure 3Blackwood Prospect lies on the Donnybrook Shear Zone which hosts the Greenbushes Mine, shown over the regional RTP 1VD Collie & Pemberton Magnetic Images.Figure 4Blackwood Prospect with NW secondary structures off the Donnybrook Shear Zone, which are likely pegmatite pathways. This is the area of the planned drone survey for September 2021 RTP 1VD Collie Magnetic Image.Figure 5: Sampling at East Kirup Prospect and planned and approved PoW for work for Q4 on the...

Trading expected to begin in the last week of July TORONTO, July 19, 2021 (GLOBE NEWSWIRE) — InterCure Ltd. (TSX: INCR.U, TASE: INCR)(dba Canndoc)(the “Company”) is pleased to announce that further to its confidential filing with the U.S. Securities and Exchange Commission (the “SEC“) of its 20F registration statement on April 20, 2021, it has filed its 20F registration statement pursuant to Securities Exchange Act of 1933 and F-1 registration statement under the Securities Act of 1933. The full statements are available on the Company’s SEDAR profile as well as on EDGAR: 20-F: https://www.sec.gov/Archives/edgar/data/0001857030/000149315221016836/form20fr12b.htm F-1: https://www.sec.gov/Archives/edgar/data/0001857030/000149315221016926/formdrsf-1.htm Listing on the NASDAQ is subject to satisfaction of all applicable...

This new national portal will give JZZ Technologies, Inc. the opportunity to give back to one of the largest communities in need in our country, namely our veterans$JZZI – JZZ Technologies, Inc.Veterans Connect USACalverton, New York , July 19, 2021 (GLOBE NEWSWIRE) — As part of its efforts to connect people in the 55+ age group, JZZ Technologies, Inc. (OTC Pink: JZZI) has launched a new national portal devoted to serving veterans at VeteransConnectUSA.org. The website covers a wide range of information designed to reach veterans and connect them to vital programs, services, and other veterans. The company’s mission is to provide an innovative informational ease-of-use platform that gives veterans the resources that offer opportunities and services they need to prosper and that enable them to reach their...

Prescription Drug User Fee Act (PDUFA) Target Goal Date set for December 23, 2021 If approved by the FDA for U.S. market access, Libervant would be the first orally delivered diazepam product for the management of seizure clustersWARREN, N.J., July 19, 2021 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the resubmission of the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters. The FDA has assigned a Prescription Drug User Fee Act (“PDUFA”) target goal date of December 23, 2021. “We are pleased with the FDA’s decision...

BUFFALO, N.Y., July 19, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, will host a live webcast on Thursday, August 5, 2021, at 10:00 AM ET to discuss its 2021 second quarter results. 22nd Century will report the Company’s second quarter 2021 results in a press release at 6:00 AM ET the same day. During the webcast, James A. Mish, chief executive officer; Michael Zercher, chief operating officer; and John Franzino, chief financial officer, will review the Company’s 2021 second quarter results, growth opportunities, and innovative strategic plans and future initiatives in the more than $1.3 trillion global addressable markets. Following prepared remarks, including an accompanying...

WEST PALM BEACH, Fla., July 19, 2021 (GLOBE NEWSWIRE) — Rennova Health, Inc. (OTC: RNVA) (OTC: RNVAW), today announced that effective at 5:00 pm, Eastern Time, on July 16, 2021 (the “Effective Time”), the Company effected a 1 for 1,000 reverse stock split of its outstanding common stock. The Company’s common stock will open for trading on Monday, July 19, 2021 on a post-split basis under the temporary trading symbol “RNVAD”. The trading symbol will revert to “RNVA” after 20 business days. As a result of the reverse stock split, every 1,000 shares of the Company’s common stock issued and outstanding on the Effective Time were consolidated into one issued and outstanding share, except to the extent that the reverse stock split resulted in any of the Company’s stockholders owning a fractional share, which fractional share will be...

London, England, July 19, 2021 (GLOBE NEWSWIRE) — Net Savings Link, Inc. (OTC Pink: NSAV), a cryptocurrency, blockchain and digital asset technology company, today announced that the Company is on schedule for the August 9, 2021 launch of its eagerly anticipated Cryptocurrency Exchange. The launch will make NSAV only the second U.S. publicly traded Cryptocurrency Exchange, following the Coinbase https://www.coinbase.com/ IPO in April, which valued Coinbase at over $85 billion. The Company will own 100% of the exchange and it will carry the NSAV brand name. The value of the global cryptocurrency market now exceeds $2 trillion. The management of NSAV believes that the Company can capture a significant share of the massive Chinese cryptocurrency market, given the expertise of its management and strategic partners. Presently, the Huobi...

RESEARCH TRIANGLE PARK, N.C., July 19, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to COSELA™ (trilaciclib) investigation for use in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer (TNBC). COSELA is currently being evaluated in PRESERVE 2, a pivotal Phase 3, randomized, double-blind, placebo-controlled study (NCT04799249) in patients receiving first- or second-line gemcitabine and carboplatin chemotherapy for TNBC. (press release) Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill unmet medical needs. The purpose is to get important...